Scientists study the relationship between obesity and diabetes, discovering that excess weight compromises the immune system, resulting in insulin resistance
(Natural News) German researchers have uncovered a critical link between obesity and diabetes. As reported by MPG.de, a sub-population of immune cells known as natural killer (NK) cells were found to increase the risk of diabetes. The researchers discovered these cells during the course of a different study, one that looked at how the immune... (Source: NaturalNews.com)
Source: NaturalNews.com - December 28, 2018 Category: Consumer Health News Source Type: news

Type 2 Diabetes Could Be a Cause of Erectile Dysfunction Type 2 Diabetes Could Be a Cause of Erectile Dysfunction
Erectile dysfunction may be caused by type 2 diabetes, mediated by insulin resistance, say European researchers, who suggest that lifestyle changes and diabetes drugs may treat the condition.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 26, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

2 Types of Diabetes Meds May Raise Heart Risk
Sulfonylureas were associated with 36 percent higher odds of complications, while basal insulin was associated with nearly twice the risk of heart disease and stroke complications, investigators found. (Source: WebMD Health)
Source: WebMD Health - December 21, 2018 Category: Consumer Health News Source Type: news

Some Second-Line T2D Options Linked With CV Risk
(MedPage Today) -- Observational study reported higher risk with sulfonylureas and basal insulin (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 21, 2018 Category: Cardiology Source Type: news

One in 37 type 2 diabetics taking a commonly prescribed drug will have a heart attack
A study by Northwestern University found that sulfonylureas and basal insulin - which are given to patients if metformin fails - make them more at risk than the newer drug class DPP-4 inhibitors. (Source: the Mail online | Health)
Source: the Mail online | Health - December 21, 2018 Category: Consumer Health News Source Type: news

Insulin, Sulfonylureas Raise Cardiovascular Risk in Diabetes Insulin, Sulfonylureas Raise Cardiovascular Risk in Diabetes
Real-world data also show no cardiovascular harm from newer glucose-lowering agents, but less benefit than was seen in randomized trials of patients with type 2 diabetes and established CVD.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

New drug cocktail for diabetes treatment
A new drug cocktail has been developed that elicits the regeneration of insulin-producing beta cells in the pancreas, according to a study published inCell Metabolism.Daily Mail (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 21, 2018 Category: Endocrinology Source Type: news

Beta Bionics Wins Readers & #039; Choice for Medtech Company of the Year
The people have spoken. Beta Bionics has been named medtech company of the year. Nearly 44% of MD+DI readers participating in a special poll voted for the Boston, MA-based company, which is developing an artificial intelligence-powered bionic pancreas, called the iLet, to help manage type 1 diabetes. Beta Bionics pulled ahead of other competitors like Boston Scientific, which was MD+DI Editor’s Choice for medtech company of the year. Each year, MD+DI's editors take a long, hard look at the medical device and diagnostics companies that rose above the ranks over the past 12 months. It can be savvy business ...
Source: MDDI - December 21, 2018 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Source Type: news

Is this a cure for diabetes? Scientists discover insulin-boosting drug 'cocktail'
Researchers from Icahn School of Medicine at Mount Sinai Hospital in New York discovered that when two drugs given in combination can proliferate cells that produce insulin. (Source: the Mail online | Health)
Source: the Mail online | Health - December 20, 2018 Category: Consumer Health News Source Type: news

Scientists Get Closer to Generating Cells Lost to Diabetes
THURSDAY, Dec. 20, 2018 -- People with diabetes often don't have enough insulin-producing beta cells to control their blood sugar, but a combination of two novel drugs may coax the body into making more of these vital cells, an early study... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 20, 2018 Category: General Medicine Source Type: news

Diabetes tech execs talk patient-centric design, device development & trust
John Timberlake has been commercializing diabetes drugs and devices for 25 years. Over the course of his career, one theme has always stood out: if you want people to use your product, it has to be made with the end-user in mind. “It’s really [about] understanding the patient first and then designing the technology around the patient,” the Valeritas CEO said this month at DeviceTalks West. The mantra of patient-centric design also rang true with Timberlake’s fellow panelist, Dr. Stephanie Habif of Tandem Diabetes Care – a California-based company that makes the t:slim X2 insulin pump. “T...
Source: Mass Device - December 19, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Featured Pharmaceuticals Wall Street Beat DeviceTalks West tandemdiabetes Valeritas Source Type: news

Novartis, China's Gan & Lee push into insulin amid diabetes epidemic
Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China's Gan& Lee on versions of three blockbuster brands as the U.S. government is seeking to slash insulin costs. (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis links with China's Gan & Lee in global insulin push
Swiss drugmaker Novartis aims to become a big player in supplying insulin to diabetics, signing a deal with China's Gan& Lee covering versions of three blockbuster brands just as the U.S. government is seeking to slash insulin costs. (Source: Reuters: Health)
Source: Reuters: Health - December 19, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Making diabetes management simpler with a tubeless pump
People using traditional insulin pumps to manage their diabetes often have to adjust their daily lives to live comfortably with a tubed pump. Insulet wants to change that. For nearly three decades, hundreds of thousands of people with diabetes have relied on insulin pumps to titrate the drug that keeps their blood sugar in check. Insulin pumps have remained largely unchanged over the years, leaving the device ripe for innovation. So when Insulet’s founder, John Brooks III, set out to find a better way to deliver insulin to his diabetic son, he looked for technologies that would make his son’s life simpler. He f...
Source: Mass Device - December 18, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Featured Wall Street Beat Insulet Source Type: news

Medical IoT and the security challenges for healthcare: What you need to know
What do healthcare providers want from medical device manufacturers concerning network and device security? Martin Nappi, Green Hills Software [Image from Shutterstock]The advent of the Internet of Things (IoT) has created enormous opportunity and profound challenges for any business looking to take on the digital transformation. But no industry faces more of a test to make this change than healthcare. Organizations that want to embrace IoT can struggle for many years in the pursuit of “going digital” and still fail. Hospitals and other healthcare providers have all the operational complexities of other bu...
Source: Mass Device - December 18, 2018 Category: Medical Devices Authors: Chris Newmarker Tags: Featured Software / IT Cybersecurity Green Hills Software Source Type: news

Researchers look at the powerful effect of mulberry fruit extract on insulin sensitivity
(Natural News) Silkworms eat the leaves of mulberry trees to spin the cocoons that become precious silk. Likewise, humans can consume an extract made from the fruit of the white mulberry (Morus alba) to attenuate symptoms of diabetes. A Korean study asserts that the fruit supplement will improve the body’s sensitivity to insulin and reduce the effects... (Source: NaturalNews.com)
Source: NaturalNews.com - December 18, 2018 Category: Consumer Health News Source Type: news

Six key facts about the market for insulins
The insulin market is commonly mischaracterized as lacking competition. In fact, robust competition among biopharmaceutical companies that produce insulin results in increasing levels of discounts and rebates that have constrained prices in recent years. Unfortunately, patients typically do not benefit from the fruits of the competitive marketplace because the price they pay at the pharmacy – set by their insurer – is tied to the undiscounted list price. (Source: The Catalyst)
Source: The Catalyst - December 17, 2018 Category: Pharmaceuticals Tags: diabetes out of pocket costs Source Type: news

Type 2 diabetes: Three foods to avoid at breakfast to control your blood sugar
TYPE 2 diabetes is a condition where the body can ’t control the amount of glucose in the blood and doesn’t respond to the hormone insulin properly. To keep your blood sugar levels under control there are three foods you should avoid having for breakfast. (Source: Daily Express - Health)
Source: Daily Express - Health - December 16, 2018 Category: Consumer Health News Source Type: news

Tidepool raises $6m to develop automated insulin delivery app
Tidepool said this week that it raised $6 million from JDRF and the Leona M. & Harry B. Helmsley Charitable Trust to support the development of Tidepool Loop – a hybrid, closed-loop automated insulin delivery app. Tidepool, a non-profit diabetes data management group, is working to create an FDA-regulated app that is compatible with multiple insulin pumps and continuous glucose monitors. Get the full story at our sister site, Drug Delivery Business News. The post Tidepool raises $6m to develop automated insulin delivery app appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - December 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Funding Roundup mHealth (Mobile Health) Pharmaceuticals Insulet Tidepool Source Type: news

Bristol Medical School researcher awarded prestigious Diabetes UK fellowship
A Bristol Medical School researcher has been awarded a prestigious Diabetes UK fellowship to understand more about adult onset type 1 diabetes. It is estimated that more than 300,000 people in the UK are living with the disease which develops when the immune system makes a mistake and destroys the cells that make insulin. (Source: University of Bristol news)
Source: University of Bristol news - December 14, 2018 Category: Universities & Medical Training Tags: Health, Grants and Awards, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School Source Type: news

Targeting PI3K Remains Complex in Cancer Therapy
Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2018 Category: Cancer & Oncology Authors: Lewis C. Cantley, PhD Source Type: news

Tidepool lands $6M grant to develop hybrid closed-loop automated insulin delivery app
The Leona M. and Harry B. Helmsley Charitable Trust and JDRF provided the grant to the diabetes management company.   (Source: mobihealthnews)
Source: mobihealthnews - December 13, 2018 Category: Information Technology Source Type: news

Sticker Shock: Transitioning Teens With T1D to Adult Care Sticker Shock: Transitioning Teens With T1D to Adult Care
For teens with type 1 diabetes, becoming an adult can mean losing continuous care and the insulin they need to survive. What can clinicians do to safely guide patients across the bridge to adult care?Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Article Source Type: news

Mylan says Sanofi loses Lantus insulin patent claims
U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan
Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials HERTFORDSHIRE, England and PITTSBURGH, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N... Biopharmaceuticals, Generics, Endocrinology, Litigation Mylan, Sanofi, Lantus, insulin glargine, Lantus SoloSTAR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 13, 2018 Category: Pharmaceuticals Source Type: news

Mylan wins lawsuit over insulin formulation patents
Mylan announced Thursday that the U.S. Patent and Trademark Appeal Board had ruled in its favor, allowing the Canonsburg-based pharmaceutical company to continue making a generic insulin glargine vial. Mylan has spent years investing in a generic insulin glargine, which is used by diabetes patients to control their blood sugar. The insulin glargine, marketed as Lantus, was created by French pharmaceutical company Sanofi and is sold in vials or as a disposable injection pen. Sanofi initiated pa tent… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 13, 2018 Category: Pharmaceuticals Authors: Luke Torrance Source Type: news

Sanofi loses Lantus patent claims against Mylan
U.S. generics drugmaker Mylan N.V. said on Thursday the U.S. Patent and Trademark Office rejected French pharma company Sanofi's patent infringement claims related to two formulations of its blockbuster insulin drug Lantus. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Mylan says patent office cancels Sanofi's Lantus patents
Mylan N.V. said on Thursday the U.S. Patent and Trademark Office invalidated French drug company Sanofi's formulation patents on its blockbuster insulin drug Lantus, ruling in favor of the U.S. drugmaker. (Source: Reuters: Health)
Source: Reuters: Health - December 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

'We're fighting for our lives': Diabetic activists take on drug companies
Diabetic activists demand drug makers answer for sky-high insulin prices. (Source: ABC News: Health)
Source: ABC News: Health - December 12, 2018 Category: Consumer Health News Tags: Health Source Type: news

How the Mediterranean Diet Can Help Women's Hearts
Modest changes in known heart disease risk factors, particularly those relating to inflammation, glucose metabolism and insulin resistance, contribute to the long-term benefit of a Mediterranean diet, researchers said. (Source: WebMD Health)
Source: WebMD Health - December 12, 2018 Category: Consumer Health News Source Type: news

Sanuwave confirms acting CEO Richardson as company head | Personnel Moves – December 12, 2018
Sanuwave said late last month that it lifted acting CEO and board chair Kevin Richardson to a permanent position in the corner office. Richardson joined the Suwanee, Ga.-based company in 2009 as board chair, and has served as acting CEO since 2014. He also served as managing partner of investment management firm Prides Capital from 2004 to September 2018. Sanuwave said that Richardson took over as the permanent CEO as of November 30, and that he will continue to serve as board chair alongside his new position heading the company, according to an SEC filing.  Common Sensing lifts Schmid to CEO, White to board chair Com...
Source: Mass Device - December 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Featured Bose Corp. Bristol-Myers Squibb Co. Common Sensing glympsebio INSIGHTEC Insulet IsoRay Merck novadipbiosciences owensminor rmsmedical Sanuwave Visioneering Technologies Zimmer Biomet Source Type: news

Minnesota lawmakers discuss reining in soaring insulin costs
Minnesota lawmakers are considering steps they could take to rein in the soaring cost of insulin, which one couple says has become so expensive that their diabetic son could no longer afford it and died (Source: ABC News: Health)
Source: ABC News: Health - December 12, 2018 Category: Consumer Health News Tags: Health Source Type: news

Why HIIT should be part of your workout routine
(Natural News) High-intensity interval training, or HIIT for short, is the latest trend that has taken the fitness world by storm, and for good reason. In fact, it’s become so popular in the U.S. that the Department of Health and Human Services has called it an effective method to “improve insulin sensitivity, blood pressure, and body... (Source: NaturalNews.com)
Source: NaturalNews.com - December 11, 2018 Category: Consumer Health News Source Type: news

Millions of Low-Risk Type 2 Diabetes Patients May Be Over-Testing Millions of Low-Risk Type 2 Diabetes Patients May Be Over-Testing
A new study finds that one in seven individuals with type 2 diabetes who don't use insulin and are at low risk of hypoglycemia monitor their blood glucose levels more often than recommended.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

'We're Fighting For Our Lives': Patients Protest Sky-High Insulin Prices
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life and death issue. Now a grassroots movement is pushing for change.(Image credit: Maddie McGarvey for NPR) (Source: NPR Health and Science)
Source: NPR Health and Science - December 10, 2018 Category: Consumer Health News Authors: Bram Sable-Smith Source Type: news

'We're Fighting For Our Lives' — Patients Protest Sky-High Insulin Prices
The price of insulin keeps going up. For people with Type 1 diabetes, high prices can be a life and death issue. Now a grassroots movement is pushing for change.(Image credit: Maddie McGarvey for NPR) (Source: NPR Health and Science)
Source: NPR Health and Science - December 10, 2018 Category: Consumer Health News Authors: Bram Sable-Smith Source Type: news

Insulin Resistance, Hyperandrogenism, Inflammation in PCOS Insulin Resistance, Hyperandrogenism, Inflammation in PCOS
What do we know about the inter-relationships of these components in the pathophysiology of PCOS?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 10, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Millions of low-risk people with diabetes may be testing their blood sugar too often
(Michigan Medicine - University of Michigan) For people with Type 2 diabetes, testing blood sugar levels becomes part of everyday life. But a new study suggests that some of them test more often than they need to. Fourteen percent of people with Type 2 diabetes who don't require insulin are buying enough test strips to test their blood sugar two or more times a day -- when they don't need to test nearly that frequently according to medical guidelines. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 10, 2018 Category: International Medicine & Public Health Source Type: news

Exercise can delay the development of Type 1 diabetes
(Natural News) When a person has Type 1 diabetes, they are unable to produce insulin, which the body needs to manage blood sugar. But according to a study led by researchers from the University of Birmingham, individuals with this lifelong condition can delay its progression through regular exercise during the first few months of diagnosis. If left untreated, Type 1... (Source: NaturalNews.com)
Source: NaturalNews.com - December 8, 2018 Category: Consumer Health News Source Type: news

New potential target for diabetes therapy identified
A new study, published inNature Metabolism, suggests that targeting a key enzyme (hormone-sensitive lipase) in fatty acid synthesis could reduce insulin resistance, and lead to new type-2 diabetes treatments.Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 7, 2018 Category: Endocrinology Source Type: news

New method for targeting insulin-producing cells
According to research, published inCell Chemical Biology, zinc may be used to selectively target drugs to pancreatic beta cells, to stimulate regeneration and insulin production.Phys.org (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 7, 2018 Category: Endocrinology Source Type: news

Cost keeps many diabetics from taking needed insulin
(Reuters Health) - The cost of insulin prevents many people with diabetes from taking it as directed, a small survey suggests. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Type 2 diabetes: A therapeutic avenue is emerging
(INSERM (Institut national de la sant é et de la recherche m é dicale)) Restoring the action of insulin is one of the keys to fighting type   2 diabetes. Researchers from Inserm led by Dominique Langin at the Institute of Cardiovascular and Metabolic Diseases (Inserm/Universit é de Toulouse) are developing a therapeutic strategy that uses the properties of an enzyme (hormone-sensitive lipase) which, when stimulating fatty-acid synthesis in the fat cells, has a beneficial effect on insulin action. This research has been published in Nature Metabolism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 5, 2018 Category: International Medicine & Public Health Source Type: news

Poor sleep health may decrease insulin sensitivity in teenagers
Research, published in theJournal of Pediatrics, suggests that late circadian timing and lack of sleep are linked to reduced insulin sensitivity in overweight teenagers.News Medical (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 4, 2018 Category: Endocrinology Source Type: news

High Cost Has Over 1 in 4 Diabetics Cutting Back on Insulin
Title: High Cost Has Over 1 in 4 Diabetics Cutting Back on InsulinCategory: Health NewsCreated: 12/3/2018 12:00:00 AMLast Editorial Review: 12/4/2018 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 4, 2018 Category: Endocrinology Source Type: news

Is the pancreas regeneration debate settled? An original theory renewed
(Diabetes Research Institute Foundation) A contentious debate among diabetes researchers has surrounded the regeneration of pancreatic insulin-producing cells: not if these cells regenerate, but rather how. Diabetes Research Institute scientists now draw categorical conclusions that pancreatic progenitors do exist. The prevailing theory, they say, is based upon an unreliable tool in an inadequate model. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2018 Category: International Medicine & Public Health Source Type: news

Diabeloop Is 2nd to Win CE Mark for Artificial Pancreas System
Medtronic has a new contender for its MiniMed 670g insulin pump, dubbed the artificial pancreas. The Dublin-based company could see a healthy competitor in Diabeloop, a small firm that recently won CE-mark for DBLG1, a hybrid closed-loop diabetes management system. DLBG1, is a patch work system that uses technologies from different companies to provide glucose measurements every five minutes. The system connects DexCom’s G6 Continuous Glucose Monitor, Kaleido’s patch insulin pump and an algorithm to a user’s phone. DLBG1 has had pretty good data -so far. In June, the co...
Source: MDDI - December 4, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Diabetic Patients Report Skimping on Tx Because of High Costs
(MedPage Today) -- Also, cost-related insulin underuse not shared with physicians (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 3, 2018 Category: American Health Source Type: news

High cost has many diabetics cutting back on insulin
"People are struggling to afford insulin, and it truly is a life-and-death situation," said a leader of the American Diabetes Association (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - December 3, 2018 Category: Consumer Health News Source Type: news

Cost-Related Insulin Underuse May Affect One in Four Patients
MONDAY, Dec. 3, 2018 -- About one in four patients report cost-related insulin underuse, which is associated with poor glycemic control, according to a research letter published online Dec. 3 in JAMA Internal Medicine. Darby Herkert, from Yale... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 3, 2018 Category: Pharmaceuticals Source Type: news